A Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
Latest Information Update: 23 Apr 2024
At a glance
- Drugs Aspacytarabine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms GFM- BST003
- 18 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2023 Results (n=36) presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 16 Aug 2021 According to a Biosight media release, the company has initiated this phase 2 study.